SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

abelacimab

NVS·NOVARTIS AG
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
Unknown; the sole remaining Phase 3 trial (LILAC-TIMI 76) is still recruiting with estimated completion in December 2027, meaning any potential regulatory filing is likely 3+ years away at best.
Why 3/10
No hard dated catalyst is scheduled within the next ~12 months: the two cancer Phase 3 trials were terminated in early 2026 (past events), and the remaining LILAC-TIMI 76 Phase 3 trial is still recruiting with estimated primary completion in December 2027. For a mega-cap diversified pharma like Novartis, this single drug represents a small fraction of enterprise value, capping the impact score.
Actionable Insight NEUTRAL

The next catalyst is the LILAC-TIMI 76 Phase 3 readout (abelacimab vs placebo in AF patients unsuitable for oral anticoagulation), but with estimated completion in December 2027, no near-term binary is on the calendar. For a mega-cap like Novartis, abelacimab is a small pipeline component; the cancer-trial failures are already priced in. Watch for any interim LILAC analysis or regulatory guidance, but the next hard catalyst is likely 12+ months away.

Price Chart

Loading chart...

Executive Summary

Abelacimab is a once-monthly injectable monoclonal antibody that blocks Factor XI, being developed by Novartis (NVS) as a potentially safer anticoagulant. It showed impressive bleeding reduction (67% vs rivaroxaban) in the Phase 2 AZALEA-TIMI 71 trial. However, in 2026 Novartis terminated two Phase 3 cancer-associated thrombosis trials after abelacimab failed to beat Eliquis. The remaining pivotal program, LILAC-TIMI 76 in atrial fibrillation patients unsuitable for oral anticoagulants, is still recruiting with estimated completion in December 2027. For a mega-cap diversified pharma, abelacimab is a modest pipeline asset with no near-term binary catalyst.

How It Works

Abelacimab is a monoclonal antibody (a lab-made protein that mimics the immune system) that blocks Factor XI, a protein in the blood that helps form clots. Unlike standard blood thinners that interfere with multiple clotting pathways and raise bleeding risk, abelacimab targets only Factor XI, the hope is it can prevent dangerous clots (strokes, pulmonary embolisms) while leaving normal wound-healing largely intact, causing less bleeding.

Trial Status

Two Phase 3 cancer-associated thrombosis trials (ASTER vs apixaban/Eliquis, and a dalteparin comparison) were terminated in early 2026 after a data review showed abelacimab failed to beat Eliquis. The remaining Phase 3 LILAC-TIMI 76 trial (abelacimab vs placebo in ~1,900-2,500 high-risk AF patients unsuitable for oral anticoagulation) is still actively recruiting across 789 sites globally, with estimated primary completion in December 2027. Additional AZALEA-TIMI 71 analyses were presented at ESC Congress 2026.

The Two-Sided Case

▲ Bull Case5
Phase 2 AZALEA-TIMI 71 (published NEJM Jan 2025) showed abelacimab reduced bleeding events by 67% vs rivaroxaban in atrial fibrillation patients, a potentially best-in-class safety signal.
The LILAC-TIMI 76 trial targets a large unmet need: AF patients who cannot take oral anticoagulants, a population with no good options today.
Abelacimab is a once-monthly subcutaneous injection, which could offer compliance advantages over daily oral pills.
Novartis has a strong cardiovascular franchise (Entresto, Leqvio) and the commercial infrastructure to maximize abelacimab if approved.
The drug's dual inhibition of Factor XI and XIa (locking the zymogen conformation) is a differentiated mechanism vs oral small-molecule competitors.
▼ Bear Case5
Two Phase 3 cancer-associated thrombosis trials (ASTER vs Eliquis and a dalteparin study) were terminated in early 2026 after abelacimab failed to beat Eliquis, raising questions about the drug's efficacy in high-risk populations.
The remaining Phase 3 LILAC-TIMI 76 trial is still recruiting with estimated completion not until December 2027, years away from any potential regulatory filing.
Novartis paid $925M upfront (up to $3.1B total) for Anthos in 2025, and the cancer-trial failures have already narrowed the drug's addressable market significantly.
The Factor XI inhibitor class faces growing competition from oral small-molecule Factor XIa inhibitors (e.g., Bayer's asundexian, BMS's milvexian) that may reach the market sooner.
For a $150B+ diversified pharma like Novartis, abelacimab is a minor pipeline asset, even a positive LILAC readout would have limited impact on the overall stock.

Upcoming Catalysts

  • LILAC-TIMI 76 Phase 3 topline readout, estimated primary completion December 2027 (no firm date set)
  • Any potential interim analysis or regulatory guidance from FDA/EMA on the AF program

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 10

Hover a chip for the title
1 novartis.com2 fiercebiotech.com3 en.wikipedia.org4 nejm.org5 clinicaltrials.gov6 novartis.com7 vcbeathealth.com8 nejm.org9 blackstone.com10 endpoints.news